ArticleToxicology mechanisms and methods2016
A framework for in vitro systems toxicology assessment of e-liquids.
Article in Toxicology mechanisms and methods, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Chemical Profiles and Toxicity of Electronic Cigarettes: An Umbrella Review and Methodological Considerations.International journal of environmental research and public health · 2023Pooled it
- Overview of Electronic Nicotine Delivery Systems: A Systematic Review.American journal of preventive medicine · 2017Pooled it
- Short halt in vaping modifies cardiorespiratory parameters and urine metabolome: a randomized trial.American journal of physiology. Lung cellular and molecular physiology · 2020Trial
- Fourth generation e-cigarette vaping induces transient lung inflammation and gas exchange disturbances: results from two randomized clinical trials.American journal of physiology. Lung cellular and molecular physiology · 2019Trial
- Safety and Efficacy of Inhaled Natural Product Powders That Enhance Mucociliary Clearance.AAPS PharmSciTech · 2026Article
- Impact of nicotine-free and nicotine-rich flavored electronic cigarette refill liquids on primary human melanocyte function.Toxicology reports · 2025Article
- Comparative toxicological assessment of cigarettes and new category products via anToxicology reports · 2024Article
- Article
- AnCurrent research in toxicology · 2024Article
- The toxic effects of electronic cigarette aerosol and cigarette smoke on cardiovascular, gastrointestinal and renal systems in mice.Scientific reports · 2023Article
- In Vitro Toxicological Investigation and Risk Assessment of E-Cigarette Aerosols Based on a Novel Solvent-Free Extraction Method.ACS omega · 2022Article
- Considerations on dosimetry for in vitro assessment of e-cigarette toxicity.Respiratory research · 2022Review
- A Review of Toxicity Mechanism Studies of Electronic Cigarettes on Respiratory System.International journal of molecular sciences · 2022Review
- Electronic cigarette smoke reduces ribosomal protein gene expression to impair protein synthesis in primary human airway epithelial cells.Scientific reports · 2021Article
- Review
- Article
- Multi-endpoint analysis of human 3D airway epithelium following repeated exposure to whole electronic vapor product aerosol or cigarette smoke.Current research in toxicology · 2021Article
- Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cellular Membrane Potential Are Predictors of E-Liquid Induced Cellular Toxicity.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020Article
- Suggested management of e-cigarette or vaping product use associated lung injury (EVALI).Journal of thoracic disease · 2020Article
- Evaluation of toxicity of aerosols from flavored e-liquids in Sprague-Dawley rats in a 90-day OECD inhalation study, complemented by transcriptomics analysis.Archives of toxicology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various electronic nicotine delivery systems (ENDS), of which electronic cigarettes (e-cigs) are the most recognized prototype, have been quickly gaining ground on conventional cigarettes because they are perceived as less harmful. Research assessing the potential effects of ENDS exposure in humans is currently limited and inconclusive. New products are emerging with numerous variations in designs and performance parameters within and across brands. Acknowledging these challenges, we present here a proposed framework for an in vitro systems toxicology assessment of e-liquids and their aerosols, intended to complement the battery of assays for standard toxicity assessments. The proposed framework utilizes high-throughput toxicity assessments of e-liquids and their aerosols, in which the device-to-device variability is minimized, and a systems-level investigation of the cellular mechanisms of toxicity is an integral part. An analytical chemistry investigation is also included as a part of the framework to provide accurate and reliable chemistry data solidifying the toxicological assessment. In its simplest form, the framework comprises of three main layers: (1) high-throughput toxicity screening of e-liquids using primary human cell culture systems; (2) toxicity-related mechanistic assessment of selected e-liquids, and (3) toxicity-related mechanistic assessment of their aerosols using organotypic air-liquid interface airway culture systems. A systems toxicology assessment approach is leveraged to enable in-depth analyses of the toxicity-related cellular mechanisms of e-liquids and their aerosols. We present example use cases to demonstrate the suitability of the framework for a robust in vitro assessment of e-liquids and their aerosols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.